| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Katz PO | |
| P2860 | cites work | Medical therapy. Management of the refractory patient | Q33850189 |
| Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease | Q39515150 | ||
| A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease | Q42662159 | ||
| Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors | Q43734554 | ||
| Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough | Q43903194 | ||
| Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis | Q43939369 | ||
| Comparison of morning and evening administration of rabeprazole for gastro‐oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double‐blind, cross‐over study | Q44654795 | ||
| Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus | Q44779979 | ||
| Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough | Q44895190 | ||
| Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? | Q45227417 | ||
| A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study | Q46383718 | ||
| Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease | Q46539046 | ||
| Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association | Q47746578 | ||
| Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. | Q51566530 | ||
| The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. | Q51970789 | ||
| Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. | Q54053126 | ||
| Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma | Q58204833 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | review article | Q7318358 |
| P304 | page(s) | 31-38 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure | |
| P478 | volume | 22 Suppl 3 |
| Q80102009 | Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect? |
| Q56774876 | Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy |
| Q80101982 | Determinants of Abnormal Supine Reflux in 24-Hour pH Recordings |
| Q41976827 | The Current Use of Proton-Pump Inhibitor Therapy in Clinical GI Practice |
Search more.